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Characterisation of breast cancer infiltrates using
monoclonal antibodies to human leucocyte antigens
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I.C.R.F. Human Tumour Immunology Group, School ofMedicine, University College London, Faculty of
Clinical Sciences, University Street, London WCIE 6JJ.
Summary Serial frozen sections from eleven patients with malignant breast tumours and five patients with
benign disease were studied by indirect immunoperoxidase using a panel of mouse monoclonal antibodies to
human leucocyte antigens. More infiltrating leucocytes were seen in tumour sections than those of benign
conditions. A considerable proportion of the infiltrating cells were T cells, and more of these were of the
suppressor/cytotoxic subset than the helper/inducer subset. The T cells were apparently not all activated as
indicated by lower levels of staining with anti HLA-DR than anti-leucocyte antibody. Diffuse staining was
sometimes seen with HLA-DR and T cell subset antibodies. Tumour cells did not stain or were only very
weakly positive with anti HLA-A, B, C.
A variety of different techniques have been used to
establish the immunological competence of the
breast cancer patient. Among the experimental
techniques which have been used to establish
immunological competence are delayed hyper-
sensitivity to skin test antigens (Stein et al., 1976),
lymphoproliferative responses (Dean et al., 1979;
Jerrells et al., 1978), numbers of leucocytes in
peripheral blood (Keller et al., 1976) and the histo-
logical appearance of the local lymph node (Cutler
et al., 1969; Heidenrich et al., 1979).
The results of these studies have been
inconclusive since there is both evidence for
immunological hyporesponsiveness in patients with
advanced disease (Lamb et al., 1962; Humphrey et
al., 1980) and data to suggest that some patients
make a response to their tumour (Black, 1973;
Bleumink et al., 1974 and Nemoto et al., 1974).
None of these studies have, however, yielded
definitive prognostic information.
Few authors have attempted to analyse
inflammatory infiltrates at the site of tumours in
detail as a prognostic indicator or as a means of
assessing a specific anti-tumour response.
Nevertheless it has been suggested that lymphocytic
infiltration of the primary tumour indicates a
favourable prognosis (Humphrey et al., 1980) and
that the infiltrate consists predominantly of tumour
directed cytotoxic lymphocytes (Schoorl et al., 1976;
Lauder, 1977; Hayry & Totterman, 1978).
With the development of monoclonal antibodies
to cell surface and cytoplasmic components of the
lymphoid and myeloid cell series, more precise
identification of infiltrating leucocytes and antigenic
changes in malignant disease is possible. In addition
the technique of indirect immunoperoxidase
staining of frozen sections allows examination of
functionally distinct cell types and antigens within
the tumour whilst preserving the precise anatomical
relationship between the tumour and infiltrating
cells. In this preliminary study biopsy material from
eleven patients with malignant disease and six
patients with benign conditions were assessed with
a panel of monoclonal antibodies to HLA Class I,
HLA Class II, leucocytes, T cells and T cell subsets.
Materials and methods
Patients
Each of the patients was admitted for biopsy of a
breast lump. Excision biopsy was performed as part
of the routine diagnostic procedure. Diagnosis was
made on the basis of histological examination of
frozen sections. In malignant cases, simple
mastectomy with removal of axillary lymph nodes
was performed immediately. (Histological diagnosis
was later confirmed on haematoxylin eosin stained
wax-embedded sections). In some cases, normal
tissue was available for examination.
Ages of patients with malignant disease were
between 37-66. The patients with benign conditions
were aged between 28-37 years.
Patient 5 had had surgery for removal of
malignant melanoma, two years prior to
mastectomy. There was no history of previous
malignant disease in any of the other women.
Patient 9 was being treated with Ibuprofen
magenta. Patient 5 was being treated with thyroxin
following thyroidectomy. The remaining patients
were receiving no drug therapy at the time of
biopsy or surgery.
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Collection ofspecimens
The specimens obtained at surgery were snap frozen
in isopentane using a dry ice/acetone coolant. They
were stored at -70°C or in liquid nitrogen. Serial
sections 6um thick were cut and air-dried and
stored at -20°C or -50°C, prior to examination.
Staining
Indirect immunoperoxidase Sections were fixed in
acetone at room temperature for 10min and then
washed for 1 min in Tris-buffered saline (TBS),
following which they were incubated in the
monoclonal first layer for 30min at room
temperature. The excess antibody was drained off
and the sections washed for min in TBS. They
were then incubated with a 1/50 dilution of horse
radish peroxidase conjugated rabbit anti-mouse
immunoglobulin. Following 30min incubation and
a 1 min wash in TBS, sections were incubated with
diaminobenzidine at a concentration of 6mg in
1Oml. Three ul H202 was added to this just before
adding to the sections. After 7min incubation the
sections were washed in 3 changes of TBS, and
then for 1 h in tap water.
Counterstaining was for 12sec in Mayer's
haematoxylin. Sections were blued in tap water,
dehydrated through a series of graded alcohols (50,
70, 90, 100% - 2 changes, 5min each) and cleared
in Xylene, 2 changes 5min each. Permanent mounts
were made in DPX.
Antisera
UCHTI (T28) is an IgGI mouse monoclonal
antibody derived from an immunisation of Balb/c
mice with human thymocytes followed by Sezary T
cells. It identifies the T3 antigen present on mature
T lymphocytes and some thymocytes (Beverley &
Callard, 1981).
DA2 is a monoclonal antibody of IgGI class with
specific for a non-polymorphic determinant of
HLA-DR (Brodsky et al., 1979). It was a gift of Dr
M. Crumpton.
Anti HLe-J (2D1) is an IgGl mouse monoclonal
antibody derived from a mouse immunised with
human peripheral blood mononuclear cells (PBL)
and identifies a determinant present on human T
cells, B cells, monocytes and granulocytes (Beverley,
1980).
2AJ This is an IgGl mouse monoclonal antibody
derived from mice immunised with human PBL
(Beverley, 1980). It identifies a human HLA-A, B,
C non polymorphic determinant.
Leu 2a/UCHT4 Leu 2a (Becton Dickinson) is an
IgG mouse anti-human monoclonal antibody
recognising the suppressor/cytotoxic T cell subset
(Ledbetter et al., 1981). UCHT4 cross inhibits with
Leu 2a in binding assays and shows identical cell
and tissue distribution patterns (unpublished data).
These two antibodies gave similar results in this
study.
Leu 3a (Becton Dickinson) is an IgGi mouse anti-
human monoclonal antibody recognizing the
helper/inducer T cell subset (Ledbetter et al., 1981).
Anti mouse immunoglobulin Horse radish
peroxidase conjugated rabbit anti mouse immuno-
globulin antiserum was purchased from Dako and
absorbed by passage through a sepharose 4B
human immunoglobulin column.
Results
Results were quantitated using a 0-++++ scale,
where + + + was the heaviest infiltrate seen
Non malignant sections (Table 1)
Similar results were seen in all cases of benign
disease and "normal" controls (macroscopically
normal tissue from mastectomy specimens).
Labelling with the anti-HLA Class I antibody
(2A1) was positive in all, but showed considerable
differences in anatomical localisation. Leucocytes
were invariably positive, but fibrous and epithelial
tissue varied considerably in the extent of labelling
from patient to patient. Some ducts were uniformly
positive and some negative while others showed
only a proportion of positive cells. Leucocytes were
found scattered throughout ducts. In no case was
the labelling uniformly positive for every cell type
(Figure 1).
The control results for HLe-1 indicate leucocyte
infiltration in all cases, but this never exceeded a
fairly modest level (+ +). Most of the staining
occurred within duct walls and cellular areas.
Labelling normally picked up scattered isolated
cells as opposed to large clumps (Figure 2). Very
little labelling occurred in fibrous areas.
Relatively few T cells as shown by UCHTI were
seen in the benign and control sections, the score
never exceeding +. Results suggest that these T
cells are probably HLA-DR positive, since there
was as much staining with DA2 as HLe-l and it
exceeded that for UCHTI. T cells were almost
exclusively confined to ducts and hyperplastic areas
and were not found in fibrous material.
Labelling with Leu 2a was seen in areas which
were UCHT1 positive, although it was difficult toHUMAN LEUCOCYTE ANTIGENS IN BREAST CANCER 151
Table I Benign conditions and "normal" sections from mastectomy patients
Reactivity with monoclonal antibody:
Patient no.
and age Histology 2AI HLe-J DA2 UCHTI Leu 2a Leu 3a
I (37) Fibrocystic + + + + + 0-* + 0- + 0- +
disease
II (28) Benign + ++ ++ ++ + 0- + 0- +
hyperplasia
III (66) Normal part + + + 0- + 0- + 0- +
from
mastectomy
patient
IV (37) Normal part 0- + 0 -+ 0- + 0-+ 0- + 0- +
from
mastectomy
patient
V (35) Benign + + + + N.D. 0-- + N.D. N.D.
hyperplasia
HLe-l is specific for all human leucocytes.
DA-2 has specificity for HLA-DR.
UCHTI is specific for all mature human T lymphocytes.
2A1 is specific for HLA-A, B, C.
Leu 2a/UCHT4 are specific for suppressor/cytotoxic T cells.
Leu 3a is specific for helper/inducer T cells.
Results of malignant tissue samples from patients III, IV & V (Table I) are
indicated in Table II, patients 3, 4 and 5.
determine what proportion of T cells were Leu
2a+, owing to the small numbers of T cells
present. Leu 3a was confined to areas which were
UCHT1 positive, and very few positive cells were
seen.
Staining by HLe-l, UCHT1, Leu 2a and Leu 3a,
was confined to cell membranes only. The anti
MHC antibodies, 2A1 and DA2 showed both
membrane and cytoplasmic staining.
Malignant tissue sections (Table II)
The staining with 2A1 was again variable both in
quantity and anatomic localisation. Leucocytes
were invariably positive as in the non-malignant
sections. Tumour cells were generally negative, or
weakly positive (Figure 3), particularly where
confined to ducts where they are easier to identify.
Fibrous areas stained variably in different patients.
Leucocyte infiltrates stained with HLe-I were
found in all patients except Patient 5 in whom
tumour had been replaced by reactive fibrosis in the
sections examined and hence could not be regarded
as a malignant area.
In 5 of the patients, + + infiltrate or greater was
seen (Patients: 1, 2, 3, 9, 11; Table II). In the
remainder at least + was seen (apart from Patient
5 already mentioned. Overall, this is considerably
greater than that seen in non-malignant samples. In
many of the patients, the infiltrates were mainly
around the edge of the tumour mass, (Patients: 1, 6,
7, 10; Table II, Figure 4) and not infiltrating the
malignant area, whereas in others stained cells were
in juxtaposition with the tumour (Figure 5). In the
cases where both malignant and "normal" material
from the same breast was available (Patient 3,
Table II, Patient III, Table I) a much greater level
of infiltrate in the malignant area than non-
malignant area of the same breast was apparent.
The staining with DA2 by comparison with HLe-Figure 1 Staining with HLA Class I (2A1) on a patient with fibrocystic disease. Many ducts are completely
negative whereas some have stained cells (arrowed). Indirect immunoperoxidase, counterstained with
haematoxylin. ( x 25.)
Figure 2 Staining with anti-leucocyte (HLe-1) in a patient with benign mammary hyperplasia. Scattered
leucocytes (some are arrowed) can be seen within the hyperplastic duct. Indirect immunoperoxidase,
counterstained with haematoxylin. ( x 50.)
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Table II Malignant conditions
Reactivity with monoclonal antibody:
Patient no. LN
and age Histological diagnosis involvement 2AJ HLehyl DA2 UCHTJ Leu 2a Leu 3a
1 (45) Schirrouscarcinoma 6/10 + + + + 0-*++ +- ++ 0- + 0- +
with tubular elements
2 (51) Invasivecarcinoma and - +-++ ++ +-++ + 0-++ 0-.+
intraduct carcinoma
3 (66) Adenocarcinoma + + + + +++ + + + + + + + +
4 (37) Intraduct and
infiltrating duct + - + + + - + + + + + 0- +
carcinoma
5 (51) Schirrous carcinoma -
this section showing - 0-+ - - - - -
reactive fibrosis
6 (50) Infiltrating duct
carcinoma with Reactive
tubular carcinoma changes only + + + + 0-. + 0-. + N.D. N.D.
7 (60) Infiltrating duct Reactive
carcinoma changesonly + + * + + ++ +-++ + -++ 0- + 0- + 0 +
8 (48) Intraductal carcinoma - + + + 0-. + N.D. N.D.
9 (57) Adenocarcinoma + + + + + + + +++ + + + + +
10 (51) Paget's disease - ++ +-+ + + ++ + + 0- +
11 (55) Lobular carcinoma non-specific
insitu reactive ++-+ + + + + + + + 0- +
changes
1, was variable. In some cases (Patients 7, 8, 9
Figure 6) the staining was obviously as much HLe-
1, whereas in the remainder of cases, it was slightly
less (Patients 2, 4, 6, 10 Table II) or more obviously
less (Patients 1, 3; Table II). This difference
manifested itself both in the number of cells stained
and the intensity of stain.
UCHTI stained the membrane of mainly
rounded cells in HLe-I positive areas only. The T
cells seen were sometimes larger than average,
suggesting that T cell blasts were being stained. T
cells were seen in all patients except Patient (5) who
was atypical as previously described. In 7 of the
patients (1, 2, 3, 4, 9, 10, 11; Table II) staining was
+ or greater, significantly more than in the non
malignant tissue. T cells constituted the majority of
leucocytes particularly in the larger infiltrates
(Figure 7).
Leu 2a always stained a high proportion of those
cells stained with UCHT1. In some cases (Patients
2, 3, 4, 9, 10, 11) the amount of labelling indicated
that the majority of UCHT1 positive cells were also
Leu 2a positive. In the remainder it appeared that a
lesser proportion were positive. In contrast staining
with Leu 3a was only + or greater in two patients
(nos. 3, 9; Table II). In the remainder only very few
Leu 3a positive cells were seen (mainly scoring
0-. +). In 2 patients (nos. 9, 11; Table II) very
diffuse labelling was seen in addition to the
characteristic discrete membrane marking seen in
the other patients. The overall level of labelling was
slightly less than that seen for Leu 2a (Figures 8
and 9).
Discussion
The importance of infiltrating leucocytes as
prognostic indicators in breast disease has been a
matter of dispute. This immunohistological study
was therefore carried out in an attempt to
determine whether the more precise identification of
leucocyte subsets which can be achieved with
monoclonal antibodies would provide useful
diagnostic or prognostic information. In addition,
identification of cells present in tumours may
provide some clues as to the nature of immune
responses to tumours.154 D.J. ROWE & P.C.L. BEVERLEY
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Figure 3 Staining with anti HLA class I (2A1) on a patient with intraduct carcinoma. The tumour is mainly
negative (at the centre of the photograph) and the surrounding cells, mainly leucocytes, and some fibrous
material, are positive. Indirect immunoperoxidase, counterstained with haematoxylin. ( x 50.)
We used as a positive control an antibody (2A1)
against a non-polymorphic determinant of HLA-A,
B, C but while this stained infiltrating leucocytes
well, the staining of normal breast tissue was
variable, some areas appearing to lack HLA
completely. Malignant breast tumour cells at best
stained weakly and in many cases appeared
negative (Figure 3). While this may be partly a
matter of the sensitivity of the immunoperoxidase
method employed, others have made similar
observations on tissue sections (Fleming et al.,
1981), and some breast derived cell lines show low
levels of expression of HLA antigens (Travers et al.,
1981). Thus it is likely that both normal and
malignant breast epithelial cells exhibit a bias
toward low expression of HLA. Since at least
cytotoxic T cells recognise target antigens in
association with HLA-A, B, C antigens
(McMichael, 1978) this may have important
implications in regard to the nature of immune
responses to tumours and the possibilities of
immunotherapy with immune cells. Whether the
apparent lack of HLA on tumour cells surrounded
by infiltrating leucocytes, represents immune
selection of tumour cell clones lacking HLA, or
that most breast tumours are derived from
epithelial cells exhibiting low levels of HLA, is
unknown.
Staining with antibodies to leucocyte
differentiation antigens revealed a number of
interesting features of breast infiltrates. In general
tumour specimens showed more leucocytes than
macroscopically normal breast tissue from tumour
patients, or specimens from patients with benignFigure 4 Staining with anti-leucocyte (HLe-1). Staining is mainly peripheral to the masses of tumour cells.
This staining pattern was only seen in malignant biopsies. Tumour cell masses are arrowed. Indirect
immunoperoxidase, counterstained with haematoxylin. ( x25.)
ligure 5 Stainng with anti-leucocyte (HLe-1) showing leucocytes scattered within the tumour mass. Indirect
immunoperoxidase, counterstained with haematoxylin. ( x 50.)156 D.J. ROWE & P.C.L. BEVERLEY
Figure 6 Staining with anti-HLA Class II (DA2) in Patient 1. In this patient, leucocytes were positive.
Indirect immunoperoxidase, counterstained with haematoxylin. ( x 25.)
breast disease. The nature of the infiltrate differed
in benign and malignant specimens. Whereas in
benign lesions (e.g. patients I-V, Table I as many
cells were stained by anti HLA-DR as by HLe-1, in
some malignant breast lesions, fewer cells were
stained by anti HLA-DR. While this might indicate
differences in the type of infiltrating leucocytes,
with more DR+ monocytes and B lymphocytes in
benign infiltrates, this does not appear to be the
case since T cells identified by UCHT1 can be
found in both types of lesion in similar proportions.
Thus it seems likely that while in malignant
infiltrates T cells may be DR-, those found in
benign breast disease carry readily detectable DR,
suggesting that they may be activated. The results
therefore present a paradox in that although the
presence of a malignant tumour leads to an influx
of leucocytes, the T cells at least do not always
show clear evidence of activation, in contrast to
infiltrating T cells in other conditions (Rowe et al.,
1983).
While leucocyte infiltration has been associated
with a favourable prognosis (Lauder et al., 1977;
Black et al., 1975) the apparent lack of activation
of the T cells present, in and around tumour, calls
in question their role. Nevertheless the cells do not
appear to represent a totally non-specific
accumulation of blood borne lymphocytes since a
feature of the infiltrates was the excess or equal
numbers of suppressor/cytotoxic (Leu 2a+)
compared to helper/inducer (Leu 3a+) cells, in
contrast to the proportions in blood. Nor is it the
rule in other sites of inflammation to find higher
numbers of suppressor/cytotoxic cells since in
biopsy specimens from polymyositis and Sjogren's
syndrome patients there is a clear excess ofHUMAN LEUCOCYTE ANTIGENS IN BREAST CANCER 157
Figure 7 Staining with anti-T cell (UCHTI) in Patient 3. Numbers of T cells can be seen mainly outside the
tumour mass (arrowed). Indirect immunoperoxidase, counterstained with haematoxylin. ( x 25.)
helper/inducers (Fox et al., 1982; Rowe et al.,
1983).
Our results raise a number of other questions. In
the patients with the heaviest infiltrates (Patients 1,
7, 9; Table II) there was evidence of axillary node
involvement which would normally be considered
to worsen the prognosis but the numbers of
patients examined in this study is too small to draw
any firm conclusions. Similarly, although leucocytes
are sometimes seen only surrounding tumour
masses, and in other specimens within the tumour,
we are as yet unable to determine whether these
differences are important or trivial, perhaps
resulting from sampling errors. In some patients
diffuse labelling with the Leu 3a antibody was seen,
the significance of this is obscure although we have
occasionally noted a similar appearance in
"normal" tonsils.
In conclusion this prelrminary study, while it
raises intriguing questions as to the role of the
infiltrating leucocytes in breast tumours, has not
delineated immunohistological features which
appear likely to provide more reliable prognostic
information than can obtained by conventional
histology.
We are grateful to Dr M. Griffiths of the Department of
Morbid Anatomy, University College London, School of
Medicine, for help in the assessment of pathological
specimens and to Susan Chandler for typing the
manuscript.Figure 8 Staining with anti-helper/inducer T cell (Leu 3a). The tumour is confined to the ducts, and stained
cells can be seen mainly below the tumour mass (arrowed). Staining is weak and diffuse. Indirect
immunoperoxidase, counterstained with haematoxylin. ( x 50.)
Figure 9 Staining with anti-suppressor/cytotoxic T cell (Leu 2a) in a section adjacent to Figure 8. Stained
cells (arrowed) are seen both above and below the tumour mass. Indirect immunoperoxidase, counterstained
with haematoxylin. ( x 50.)
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